Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CGEM Cullinan Therapeutics	$7.62 -3.7%	$8.08	$6.85 ▼ $28.11	$449.69M	-0.07	588,054 shs	1.25 million shs
MCRB Seres Therapeutics	$7.37 -6.5%	$11.38	$6.64 ▼ $30.60	$64.36M	2.89	147,201 shs	126,967 shs
MGTX MeiraGTx	$5.15 -8.4%	$6.37	$3.85 ▼ $8.75	$411.75M	1.3	349,726 shs	1.01 million shs
OPT Opthea	$3.41 +7.2%	$3.39	$1.79 ▼ $6.30	$524.84M	1.12	26,658 shs	3,000 shs

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CGEM Cullinan Therapeutics	-3.67%	-2.93%	-1.17%	-22.95%	-70.84%
MCRB Seres Therapeutics	-6.47%	-13.80%	-37.60%	-54.95%	-61.82%
MGTX MeiraGTx	-8.36%	-12.27%	-0.96%	-20.03%	+0.19%
OPT Opthea	0.00%	0.00%	0.00%	-33.53%	-7.84%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CGEM Cullinan Therapeutics	2.4112 of 5 stars	3.5	2.0	0.0	2.2	2.5	0.6
MCRB Seres Therapeutics	3.4764 of 5 stars	2.9	3.0	4.6	1.7	1.7	0.0
MGTX MeiraGTx	4.568 of 5 stars	3.5	3.0	4.8	1.7	2.5	1.9
OPT Opthea	0.8384 of 5 stars	2.1	1.0	0.0	2.7	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CGEM Cullinan Therapeutics	3.00	Buy	$32.00	319.95% Upside
MCRB Seres Therapeutics	1.80	Reduce	$73.67	899.55% Upside
MGTX MeiraGTx	3.00	Buy	$24.50	375.73% Upside
OPT Opthea	2.17	Hold	$1.33	-60.90% Downside

Current Analyst Ratings Breakdown

Latest MCRB, OPT, CGEM, and MGTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/12/2025	CGEM Cullinan Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $24.00
5/8/2025	MCRB Seres Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$1.25 ➝ $6.00
4/16/2025	CGEM Cullinan Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$33.00 ➝ $33.00
3/25/2025	OPT Opthea	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$12.00 ➝ $2.00
3/25/2025	OPT Opthea	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform	$12.00 ➝ $1.00
3/25/2025	OPT Opthea	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Underperform	$8.00 ➝ $1.00
3/24/2025	OPT Opthea	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
3/24/2025	OPT Opthea	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
3/20/2025	MCRB Seres Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00 ➝ $25.00
3/17/2025	MGTX MeiraGTx	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$11.00 ➝ $13.00
3/14/2025	MCRB Seres Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sell ➝ Sell	$20.00 ➝ $15.00

(Data available from 5/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CGEM Cullinan Therapeutics	N/A	N/A	N/A	N/A	$10.61 per share	N/A
MCRB Seres Therapeutics	$126.33M	0.51	N/A	N/A	($0.35) per share	-21.06
MGTX MeiraGTx	$33.28M	12.37	N/A	N/A	$2.17 per share	2.37
OPT Opthea	$87.67K	5,986.77	N/A	N/A	($0.56) per share	-6.09

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CGEM Cullinan Therapeutics	-$153.16M	-$2.91	N/A	N/A	N/A	N/A	-26.54%	-25.32%	N/A
MCRB Seres Therapeutics	-$113.72M	-$4.60	N/A	N/A	N/A	N/A	N/A	-55.08%	N/A
MGTX MeiraGTx	-$84.03M	-$2.13	N/A	13.55	0.37	-633.05%	-146.38%	-53.05%	N/A
OPT Opthea	-$220.24M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A

Latest MCRB, OPT, CGEM, and MGTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/21/2025	Q1 2025	CGEM Cullinan Therapeutics	-$0.80	N/A	N/A	N/A	N/A	N/A
5/13/2025	Q1 2025	MGTX MeiraGTx	-$0.38	-$0.51	-$0.13	-$0.51	$4.44 million	$1.93 million
5/8/2025	Q1 2025	CGEM Cullinan Therapeutics	-$0.78	-$0.74	+$0.04	-$0.74	N/A	N/A
5/7/2025	Q1 2025	MCRB Seres Therapeutics	-$0.67	-$2.24	-$1.57	$3.75	$10.00 million	N/A
3/13/2025	Q4 2024	MGTX MeiraGTx	-$0.48	-$0.50	-$0.02	-$0.50	$1.50 million	$21.39 million
2/27/2025	Q4 2024	CGEM Cullinan Therapeutics	-$0.75	-$0.73	+$0.02	-$0.73	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CGEM Cullinan Therapeutics	N/A	N/A	N/A	N/A	N/A
MCRB Seres Therapeutics	N/A	N/A	N/A	N/A	N/A
MGTX MeiraGTx	N/A	N/A	N/A	N/A	N/A
OPT Opthea	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CGEM Cullinan Therapeutics	N/A	24.46	24.46
MCRB Seres Therapeutics	N/A	1.12	1.12
MGTX MeiraGTx	0.86	2.34	2.34
OPT Opthea	N/A	2.94	2.94

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CGEM Cullinan Therapeutics	86.31%
MCRB Seres Therapeutics	59.34%
MGTX MeiraGTx	67.48%
OPT Opthea	55.95%

Insider Ownership

Company	Insider Ownership
CGEM Cullinan Therapeutics	7.16%
MCRB Seres Therapeutics	4.70%
MGTX MeiraGTx	7.50%
OPT Opthea	3.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CGEM Cullinan Therapeutics	30	59.02 million	54.69 million	Optionable
MCRB Seres Therapeutics	330	8.73 million	162.03 million	Optionable
MGTX MeiraGTx	300	79.95 million	71.59 million	Optionable
OPT Opthea	8	153.91 million	148.98 million	Not Optionable

MCRB, OPT, CGEM, and MGTX Headlines

Recent News About These Companies

Hsbc Holdings PLC Makes New Investment in Opthea Limited (NASDAQ:OPT)

May 9, 2025 | marketbeat.com

Biotech Dimerix lands $940m licensing deal for kidney drug sales

May 1, 2025 | afr.com

Phil King’s Regal successfully bets against Tesla, Nvidia

May 1, 2025 | afr.com

Opthea Limited (NASDAQ:OPT) Receives Average Recommendation of "Hold" from Analysts

April 22, 2025 | marketbeat.com

'No one is happy': Regal stockpickers face financial hit after Opthea blow up

April 21, 2025 | capitalbrief.com

Regal’s King says his hedge funds will recover from March madness

April 16, 2025 | afr.com

Regal: Don’t catch the falling knife, wait for it to stick in the floor

April 16, 2025 | msn.com

Opthea to lay off approximately 65% of company

April 10, 2025 | ophthalmologytimes.com

Opthea lays off 65% of staff after back-to-back phase 3 eye disease flops

April 10, 2025 | fiercebiotech.com

BELL POTTER SECURITIES Downgrades Opthea (CKDXF)

April 9, 2025 | msn.com

BELL POTTER SECURITIES Downgrades Opthea Limited - Depositary Receipt () (OPT)

April 9, 2025 | msn.com

ASX drops as US jumbo China tariff takes effect

April 9, 2025 | afr.com

Opthea Limited (CKDXF) was downgraded to a Sell Rating at Bell Potter

April 3, 2025 | markets.businessinsider.com

Phil King’s Regal writes Opthea to zero and backs off risky bets

April 2, 2025 | afr.com

Opthea Ends Development of Sozinibercept in Wet AMD

March 31, 2025 | marketwatch.com

LifeMine’s restructuring; Europe won’t renew authorization for PTC’s Duchenne drug

March 31, 2025 | endpts.com

Opthea terminates COAST trial, announces ShORe trial misses endpoint

March 31, 2025 | markets.businessinsider.com

Opthea scraps wet AMD program after eye drug loses out to Lucentis in latest phase 3 fail

March 31, 2025 | fiercebiotech.com

Opthea discontinues development of sozinibercept in wet AMD

March 31, 2025 | healio.com

Opthea Announces Decision to Discontinue Wet AMD Trials

March 31, 2025 | globenewswire.com

Opthea Limited’s Securities Suspended Due to Financial Concerns

March 30, 2025 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Tesla's Band-Aid Has Been Ripped Off: Rally Mode Engaged
By Sam Quirke | April 30, 2025
View Tesla's Band-Aid Has Been Ripped Off: Rally Mode Engaged
Here's Why Call Option Traders Love Dutch Bros Stock
By Gabriel Osorio-Mazilli | May 12, 2025
View Here's Why Call Option Traders Love Dutch Bros Stock
Texas Instruments: Earnings Beat, Upbeat Guidance Fuel Recovery
By Jeffrey Neal Johnson | April 27, 2025
View Texas Instruments: Earnings Beat, Upbeat Guidance Fuel Recovery
CrowdStrike Stock Is a Buy as Cyberthreat Environment Expands
By Chris Markoch | April 15, 2025
View CrowdStrike Stock Is a Buy as Cyberthreat Environment Expands
Unusual Options Activity Signals Bullish Shift to Travel Stocks
By Gabriel Osorio-Mazilli | April 22, 2025
View Unusual Options Activity Signals Bullish Shift to Travel Stocks

MCRB, OPT, CGEM, and MGTX Company Descriptions

Cullinan Therapeutics NASDAQ:CGEM

$7.62 -0.29 (-3.67%)

As of 05/13/2025 04:00 PM Eastern

Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Seres Therapeutics NASDAQ:MCRB

$7.37 -0.51 (-6.47%)

Closing price 05/13/2025 04:00 PM Eastern

Extended Trading

$7.45 +0.08 (+1.09%)

As of 07:38 AM Eastern

Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

MeiraGTx NASDAQ:MGTX

$5.15 -0.47 (-8.36%)

Closing price 05/13/2025 04:00 PM Eastern

Extended Trading

$5.45 +0.30 (+5.84%)

As of 08:08 AM Eastern

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.

Opthea NASDAQ:OPT

$3.41 +0.23 (+7.23%)

As of 05/12/2025

Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead product candidate is Sozinibercept (OPT 302), a soluble form of vascular endothelial growth factor receptor-3 VEGFR-3, currently under Phase 3 clinical development as a novel therapy for wet age-related macular degeneration and diabetic macular edema. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time